Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis

Oncotarget. 2017 Apr 18;8(16):27645-27660. doi: 10.18632/oncotarget.15291.

Abstract

It remains controversial that the impacts of individual HLA locus mismatches on clinical outcomes of patients receiving unrelated-donor hematopoietic cell transplantation (HCT), as compared to HLA allele matched controls. We conducted a meta-analysis to address these issues. Four databases (PubMed, Embase, Web of Science and the Cochrane Library) were searched to select eligible studies. All donor-recipient pairs were high-resolution typing for HLA-A, -B, -C, -DRB1, DQB1 and DPB1 loci. Multivariate-adjusted hazard ratios (HRs) were extracted and pooled using a random-effects model. A total of 36 studies were included, with 100,072 patients receiving HCT. Surprisingly, we found that HLA-DQB1 locus mismatches had no significantly increased risk of multiple outcomes including acute and chronic graft-versus-host disease (GVHD), overall mortality and disease relapse (HR, 1.07; P = .153; HR, 1.07; P = .271; HR, 1.09; P = .230; HR, 1.07; P = .142 and HR, 1.02; P = .806, respectively). Mismatched HLA-DPB1 was significantly associated with a reduced risk of disease relapse (HR, 0.74; P < .001) but not with increased risks of transplant-related mortality (TRM) and overall mortality (HR, 1.09; P = .591; I2 = 74.2% and HR, 1.03; P = .460, respectively). In conclusion, HLA-DQB1 locus mismatches is a permissive mismatching. HLA-DPB1 locus mismatches significantly protect against leukemia relapse. Refining effects of individual HLA locus mismatches contributes to predicting prognosis of patients receiving unrelated donor HCT.

Keywords: HLA locus; hematopoietic cell transplantation; meta-analysis; unrelated donor.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Alleles
  • Cell Lineage
  • Graft Survival
  • Graft vs Host Disease / diagnosis
  • Graft vs Host Disease / etiology
  • HLA Antigens / genetics*
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Mortality
  • Patient Outcome Assessment
  • Polymorphism, Genetic
  • Quantitative Trait Loci*
  • Recurrence
  • Transplantation, Homologous
  • Unrelated Donors*

Substances

  • HLA Antigens